67% of HCPs knew of EULAR’s CVD risk guidelines in RMDs—but few could apply them. ✅ Only 13% linked SLE control to CVD risk 🚫 0% picked correct BP/statin use in RA/AS/PsA Barriers? Time, knowledge, and local guideline gaps. POS0410-HPR @RheumNow #EULAR2025

#Relapsing_Polychondritis Main differential diagnosis is GPA 🔺️No ANCA and no renal involvement in relapsing polychondritis @Lupusreference #EULAR2025 @RheumNow https://t.co/QUJZ3EDjj3

“That is why this task force continues to say: nothing is better than methotrexate and glucocorticoids to start” - Josef Smolen, on RA treatment #EULAR2025 @RheumNow https://t.co/AbkgWS8tvH

The key changes for the new 2025 EULAR recommendations on RA treatment #EULAR2025 @RheumNow https://t.co/dp5LnoFdpW

#EULAR new #RA #recommendations J Smolen presents justification for #MTX +#glucocorticoids at onset do you agree? Diff from #ACR #EULAR #Recommendations II #EULAR2025 @RheumNow https://t.co/wqCX5HA87q

URAT1 inhibitors look like the way to go in Gout! Presented in multiple abstracts at #EULAR2025 Pozdeutinurad Ph2 long term safety data chronic gouty arthritis + tophi OP0300 Ph3 RCT of Ruzinurad in hyperuricemia/primary gout OP0302 Ph 2b RCT of SAP-001 Refractory Gout +/-

EULAR Points to consider for the definition of #D2M #Psoriatic_Arthritis 1️⃣ Failure >= 2 b/tsDMARDs with >=2 different MOA 2️⃣ Perceived as problematic 3️⃣ Evidence of persistent disease (active disease, EMM, inflammation) #EULAR2025 @RheumNow https://t.co/69nFEYntF0

EULAR PtC for the definition of #TR (Trt Refractory) #Psoriatic_Arthritis #D2M 1️⃣ Failure >= 2 b/tsDMARDs 2️⃣ Problematic 3️⃣ Evidence of persistent disease (inflammation is mandatory) + 4️⃣ Exclude comorbidities, psychosocial factors, failure due to SE/CI #EULAR2025 @RheumNow https://t.co/8nx26mWX3C

@RheumNow When it comes to ORAL Surveillance and the 2025 EULAR recommendations, the same sensibility remains. Appropriate caution based on the RCT, despite observational data, but we’ll see what is yet to come. Plenty to watch this space for #EULAR2025 @RheumNow https://t.co/fIxHRGDFcK

Deucravacitinib, the first oral TYK2 inhibitor, delivers in PsA: ✅ ACR20: 54% vs 34% (placebo) ✅ Skin, joints, fatigue, QoL 📉 Post hoc: less radiographic progression No new safety signals at W16. LB0001 @RheumNow #EULAR2025